These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance. Kingma PS; Burden DA; Osheroff N Biochemistry; 1999 Mar; 38(12):3457-61. PubMed ID: 10090731 [TBL] [Abstract][Full Text] [Related]
24. The regulation of DNA topoisomerase II by casein kinase II. Alghisi GC; Roberts E; Cardenas ME; Gasser SM Cell Mol Biol Res; 1994; 40(5-6):563-71. PubMed ID: 7735331 [TBL] [Abstract][Full Text] [Related]
25. Retinoic acid and phorbol ester induced hyperphosphorylation of topoisomerase II-alpha is an early event in HL-60 human leukaemia cell differentiation: effect on topoisomerase activity and etoposide sensitivity. Chresta CM; Hall BF; Francis GE Leukemia; 1995 Aug; 9(8):1373-81. PubMed ID: 7643627 [TBL] [Abstract][Full Text] [Related]
26. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434 [TBL] [Abstract][Full Text] [Related]
27. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity. Barret JM; Calsou P; Larsen AK; Salles B Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322 [TBL] [Abstract][Full Text] [Related]
28. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Nitiss JL; Liu YX; Harbury P; Jannatipour M; Wasserman R; Wang JC Cancer Res; 1992 Aug; 52(16):4467-72. PubMed ID: 1322791 [TBL] [Abstract][Full Text] [Related]
29. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene. Pommier Y; Orr A; Kohn KW; Riou JF Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259 [TBL] [Abstract][Full Text] [Related]
30. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Potmesil M; Hsiang YH; Liu LF; Bank B; Grossberg H; Kirschenbaum S; Forlenza TJ; Penziner A; Kanganis D Cancer Res; 1988 Jun; 48(12):3537-43. PubMed ID: 2836060 [TBL] [Abstract][Full Text] [Related]
31. DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II. Caldecott K; Banks G; Jeggo P Cancer Res; 1990 Sep; 50(18):5778-83. PubMed ID: 2168280 [TBL] [Abstract][Full Text] [Related]
32. Effect of cell proliferation and chromatin conformation on intercalator-induced, protein-associated DNA cleavage in human brain tumor cells and human fibroblasts. Zwelling LA; Estey E; Silberman L; Doyle S; Hittelman W Cancer Res; 1987 Jan; 47(1):251-7. PubMed ID: 3024817 [TBL] [Abstract][Full Text] [Related]
33. Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance. Leontiou C; Lakey JH; Lightowlers R; Turnbull RM; Austin CA Mol Pharmacol; 2006 Jan; 69(1):130-9. PubMed ID: 16239602 [TBL] [Abstract][Full Text] [Related]
34. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. Ganapathi R; Constantinou A; Kamath N; Dubyak G; Grabowski D; Krivacic K Mol Pharmacol; 1996 Aug; 50(2):243-8. PubMed ID: 8700130 [TBL] [Abstract][Full Text] [Related]
35. Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of ATP hydrolysis: evidence for a common mechanism of regulation by phosphorylation. Corbett AH; Fernald AW; Osheroff N Biochemistry; 1993 Mar; 32(8):2090-7. PubMed ID: 8383533 [TBL] [Abstract][Full Text] [Related]
36. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage. Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498 [TBL] [Abstract][Full Text] [Related]
37. Effect of casein kinase II-mediated phosphorylation on the catalytic cycle of topoisomerase II. Regulation of enzyme activity by enhancement of ATP hydrolysis. Corbett AH; DeVore RF; Osheroff N J Biol Chem; 1992 Oct; 267(28):20513-8. PubMed ID: 1328202 [TBL] [Abstract][Full Text] [Related]
38. The effect of staurosporine on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells. Zwelling LA; Altschuler E; Mayes J; Hinds M; Chan D Cancer Chemother Pharmacol; 1991; 29(1):48-52. PubMed ID: 1660353 [TBL] [Abstract][Full Text] [Related]
39. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Robinson MJ; Corbett AH; Osheroff N Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484 [TBL] [Abstract][Full Text] [Related]
40. Phosphorylation of the C-terminal domain of yeast topoisomerase II by casein kinase II affects DNA-protein interaction. Dang Q; Alghisi GC; Gasser SM J Mol Biol; 1994 Oct; 243(1):10-24. PubMed ID: 7932731 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]